{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:56:57Z","timestamp":1794023817207,"version":"4.8.0"},"reference-count":38,"publisher":"Royal College of General Practitioners","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJGP Open"],"accepted":{"date-parts":[[2024,1,17]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Depression is the second most common chronic condition affecting women of reproductive age; 23.4% of women enter pregnancy with depression and use of selective serotonin reuptake inhibitors (SSRIs) in pregnancy is often necessary for maternal wellbeing. However, SSRI use during pregnancy can cause congenital malformations, postpartum haemorrhage (PPH), and persistent pulmonary hypertension of the newborn (PPHN). In UK primary care, prescribing formularies are one medium by which prescribers are provided with local medicines advice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim<\/jats:title>\n<jats:p>To review all local prescribing formularies with respect to prescribing SSRIs in women of reproductive age, during pregnancy, and during breastfeeding.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design &amp; setting<\/jats:title>\n<jats:p>A systematic review of prescribing formularies in England and Wales.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>A systematic keyword search of all clinical commissioning group and Integrated Care Board websites in England and Local Health Board websites in Wales was undertaken between December 2021\u201322 to identify prescribing formularies. Data were extracted on prescribing guidance for SSRIs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>\nSeventy-four prescribing formularies were reviewed. Of these, 14.9% (\n<jats:italic>n<\/jats:italic>\n= 11\/74) provided links to the Medicines and Healthcare products Regulatory Agency guidance on congenital abnormalities associated with SSRIs, 28.4% (\n<jats:italic>n<\/jats:italic>\n= 21\/74) provided links to guidance on PPH risk, and 1.4% (\n<jats:italic>n<\/jats:italic>\n= 1\/74) provided links to guidance on PPHN. Specific local guidance was given on SSRI prescribing for women of reproductive age, during pregnancy, and during breastfeeding in 12.2% (\n<jats:italic>n<\/jats:italic>\n= 9\/74), 23.0% (\n<jats:italic>n<\/jats:italic>\n= 17\/74), and 21.6% (\n<jats:italic>n<\/jats:italic>\n= 16\/74) of formularies, respectively.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our results suggest that prescribers may be poorly informed by local formularies about the risks of SSRI use around pregnancy. This could place babies at increased risk of unintentional SSRI exposure.<\/jats:p>\n<\/jats:sec>","DOI":"10.3399\/bjgpo.2023.0255","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:45:24Z","timestamp":1706183124000},"page":"BJGPO.2023.0255","source":"Crossref","is-referenced-by-count":1,"title":["Selective serotonin reuptake inhibitors (SSRIs) in women of reproductive age: a systematic review of local formularies"],"prefix":"10.3399","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0393-4266","authenticated-orcid":false,"given":"Elizabeth","family":"Lovegrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-8052","authenticated-orcid":false,"given":"Alice","family":"Maidwell-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5432-7437","authenticated-orcid":false,"given":"Beth","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-5260","authenticated-orcid":false,"given":"Miriam","family":"Santer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2024090602150994000_8.2.BJGPO.2023.0255.1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1906"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7641"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.3","unstructured":"NHS Digital (2015) Health Survey for England, 2014, accessed. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/health-survey-for-england-2014. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2453"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-022-04442-3"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02722-5"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.7","unstructured":"National Institute for Health and Care Excellence (2023) Depression in adults: treatment and management. NICE guideline [NG222], accessed. https:\/\/www.nice.org.uk\/guidance\/ng222. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.8","unstructured":"National Institute for Health and Care Excellence (2011) Generalised anxiety disorder and panic disorder in adults: management, accessed. https:\/\/www.nice.org.uk\/guidance\/cg113\/resources\/generalised-anxiety-disorder-and-panic-disorder-in-adults-management-pdf-35109387756997. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.9","unstructured":"MacKenna B (2019) What are the most commonly prescribed medicines? Top 10 prescribed medicines in NHS England primary care for 2019, accessed. https:\/\/www.bennett.ox.ac.uk\/blog\/2020\/03\/what-are-the-most-commonly-prescribed-medicines-top-10-prescribed-medicines-in-nhs-england-primary-care-for-2019\/. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.10","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19m02552"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1508"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.12","unstructured":"Public Health England (2020) Prescribed medicines review: summary, accessed. https:\/\/www.gov.uk\/government\/publications\/prescribed-medicines-review-report\/prescribed-medicines-review-summary. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2021.100205"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.14","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2021.0020"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.15","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2021.0561"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.16","unstructured":"NHS Business Services Authority (2023) Medicines Used in Mental Health \u2013 England \u2013 2015\/16 to 2021\/22, accessed. https:\/\/www.nhsbsa.nhs.uk\/statistical-collections\/medicines-used-mental-health-england\/medicines-used-mental-health-england-201516-202122. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.17","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2741"},{"issue":"3","key":"2024090602150994000_8.2.BJGPO.2023.0255.18","first-page":"242","article-title":"Risks of untreated depression in pregnancy","author":"Chan","year":"2014","journal-title":"Can Fam Physician"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.19","unstructured":"Dalfen AK (2019) in Psychiatry in Primary Care A Concise Canadian Pocket Guide (2nd edition), eds Goldbloom DS Davine J (CAMH, Toronto, ON) In. Perinatal mood and anxiety disorders."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.0934"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103545"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.22","unstructured":"Knight MBK Felker A Patel R et al (2021) Saving lives, improving mothers\u2019 care core report - lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2019-21, accessed. https:\/\/www.npeu.ox.ac.uk\/assets\/downloads\/mbrrace-uk\/reports\/maternal-report-2021\/MBRRACE-UK_Maternal_Report_2021_-_FINAL_-_WEB_VERSION.pdf. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.23","unstructured":"Knight MBK Patel R Shakespeare J et al (2022) Saving lives, improving mothers\u2019 care core report - lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2018-20, accessed. https:\/\/hubble-live-assets.s3.eu-west-1.amazonaws.com\/birth-companions\/file_asset\/file\/590\/MBRRACE-UK_Maternal_MAIN_Report_2022_v10.pdf. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.24","unstructured":"UK Government (2023) Fluoxetine: possible small risk of congenital cardiac defects, accessed. https:\/\/www.gov.uk\/drug-safety-update\/fluoxetine-possible-small-risk-of-congenital-cardiac-defects. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.25","unstructured":"UK Government (2023) SSRIs and SNRIs: risk of persistent pulmonary hypertension in the newborn, accessed. https:\/\/www.gov.uk\/drug-safety-update\/ssris-and-snris-risk-of-persistent-pulmonary-hypertension-in-the-newborn. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.26","unstructured":"UK Government (2023) SSRI\/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery, accessed. https:\/\/www.gov.uk\/drug-safety-update\/ssri-slash-snri-antidepressant-medicines-small-increased-risk-of-postpartum-haemorrhage-when-used-in-the-month-before-delivery. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.27","unstructured":"National Institute for Health and Care Excellence (2023) Antenatal and postnatal mental health: clinical management and service guidance, accessed. https:\/\/www.nice.org.uk\/guidance\/cg192\/resources\/antenatal-and-postnatal-mental-health-clinical-management-and-service-guidance-pdf-35109869806789. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.28","unstructured":"Royal College of Obstetricians and Gynaecologists (2023) Management of women with mental health issues during pregnancy and the postnatal period (Good Practice No.14), accessed. https:\/\/www.rcog.org.uk\/guidance\/browse-all-guidance\/good-practice-papers\/management-of-women-with-mental-health-issues-during-pregnancy-and-the-postnatal-period-good-practice-no14\/. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsrh-2021-201164"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62071-1"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.31","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp20X712997"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067987"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.33","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20599"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04269.x"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.35","unstructured":"National Institute for Health and Care Excellence (2014) Developing and updating local formularies medicines practice guideline [MPG1], accessed. https:\/\/www.nice.org.uk\/guidance\/mpg1. 29 Apr 2024."},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.36","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15197"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022009"},{"key":"2024090602150994000_8.2.BJGPO.2023.0255.38","unstructured":"ConcePTION (2023) The Work Packages, accessed. https:\/\/www.imi-conception.eu\/background\/work\/. 29 Apr 2024."}],"container-title":["BJGP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGPO.2023.0255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:32:40Z","timestamp":1725633160000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgpopen.org\/lookup\/doi\/10.3399\/BJGPO.2023.0255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,29]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.3399\/BJGPO.2023.0255"],"URL":"https:\/\/doi.org\/10.3399\/bjgpo.2023.0255","relation":{},"ISSN":["2398-3795"],"issn-type":[{"value":"2398-3795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}